These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dangerous supplements: still at large. Consum Rep; 2004 May; 69(5):12-7. PubMed ID: 15104077 [No Abstract] [Full Text] [Related]
4. Comments on public health concerns: facts, fiction, and gaps in knowledge. Hoffman FA Thromb Res; 2005; 117(1-2):177-8; discussion 201-7. PubMed ID: 16183104 [No Abstract] [Full Text] [Related]
5. Conference summary and recommendations for research. Hasan AA; Marder VJ Thromb Res; 2005; 117(1-2):229-30. PubMed ID: 16225912 [No Abstract] [Full Text] [Related]
6. Comments on public health concerns: facts, fiction and gaps in knowledge. Hoffman FA Thromb Res; 2005; 117(1-2):177-84; discussion 201-7. PubMed ID: 16182345 [No Abstract] [Full Text] [Related]
7. Dietary supplements in the US: pitfalls and safety. Walker R; Hilsden RJ Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):60-1. PubMed ID: 16456554 [No Abstract] [Full Text] [Related]
8. The hype surrounding nutraceutical supplements: do consumers get what they deserve? Lockwood GB Nutrition; 2007 Oct; 23(10):771-2. PubMed ID: 17716868 [No Abstract] [Full Text] [Related]
9. Ignorance is not bliss. Prather E Tex Med; 2005 Apr; 101(4):45-7. PubMed ID: 16134794 [No Abstract] [Full Text] [Related]
10. The interaction of dietary supplements with antithrombotic agents: scope of the problem. Marder VJ Thromb Res; 2005; 117(1-2):7-13; discussion 39-42. PubMed ID: 16076481 [No Abstract] [Full Text] [Related]
11. Remarks on clinical data concerning dietary supplements that affect antithrombotic therapy. Lichtenstein AH Thromb Res; 2005; 117(1-2):71-3; discussion 113-5. PubMed ID: 15951007 [No Abstract] [Full Text] [Related]
14. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview. Woo JJ Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311 [No Abstract] [Full Text] [Related]
15. Dietary supplements in the management of diabetes: potential risks and benefits. Geil P; Shane-McWhorter L J Am Diet Assoc; 2008 Apr; 108(4 Suppl 1):S59-65. PubMed ID: 18358258 [TBL] [Abstract][Full Text] [Related]
16. FDA perspectives on supplement use by patients on antithrombotic therapy. Kim MJ Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297 [No Abstract] [Full Text] [Related]
17. The interference of botanicals and nutraceuticals with the effects of antithrombotic agents: how should the available evidence be weighed? De Smet PA Thromb Res; 2005; 117(1-2):19-24; discussion 39-42. PubMed ID: 16239022 [No Abstract] [Full Text] [Related]
18. The science and marketing of dietary supplements. Fraunfelder FW Am J Ophthalmol; 2005 Aug; 140(2):302-4. PubMed ID: 16086950 [No Abstract] [Full Text] [Related]
19. Quality of manufacturer provided information on safety and efficacy claims for dietary supplements for colonic health. Hass DJ; Lewis JD Pharmacoepidemiol Drug Saf; 2006 Aug; 15(8):578-86. PubMed ID: 16700078 [TBL] [Abstract][Full Text] [Related]
20. Regulation of dietary supplement advertising: current claims of interest to the Federal Trade Commission, Food and Drug Administration and National Advertising Division. Villafranco JE; Lustigman AB Food Drug Law J; 2007; 62(4):709-25. PubMed ID: 18557227 [No Abstract] [Full Text] [Related] [Next] [New Search]